QIAGEN N.V.

Key metrics

Financial performance

Over the last 9 fiscal years QIAGEN N.V.'s revenue grew from $1.34B to $2.09B, a compound annual growth rate of 5.1%. Net profit margin expanded from 6.0% to 20.3% over the same period - every figure below comes from the company's audited annual filings.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (500 filings)

Recent press releases

• QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows2026-05-20

  New AI-powered scientific platform available on www.qiagen.com connects experiment planning, product discovery and workflow support through a single conversational interface

• QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA2026-05-19

  Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights’ curated biomedical knowledge bases

• QIAGEN Plans to Launch New Fully Automated Sample to Insight Workflow and an AI-Enabled Risk Stratification Tool to Advance QuantiFERON Latent TB Testing2026-05-07

  Ambition to support high-throughput laboratories in efficiently scaling latent tuberculosis (TB) screening as testing volumes continue to grow

• QIAGEN Reports Full Results for Q1 20262026-05-06

  Net sales rise 2% to $492 million on a reported basis, and -1% at constant exchange rates (CER) vs. outlook for at least 1% CER growth

• QIAGEN reports preliminary Q1 2026 results: achieves adjusted EPS outlook with mixed sales trends; updates full-year 2026 outlook2026-04-27

  Sample technologies, QIAcuity and QDI deliver solid growth; QuantiFERON sales affected by significantly lower immigration testing demand

Similar companies

The largest companies sharing QIAGEN N.V.'s SEC industry classification (biological products, (no diagnostic substances)).